SecBot SecBot
6-K ·Filed May 12, 2026

HMDCF

HUTCHMED (China) Ltd
NEUTRAL
Impact 1/10
Horizonimmediate Processed5mo ago SEC0001648257-26-000031
Notable filing: 6-K
Actionable Insight • Neutral

No immediate trading action warranted. Monitor future filings for any actual share issuance or repurchase activity under the newly approved mandates, which could affect share count and capital structure.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
HMDCF ▼ -23.40% at T+60d
NEUTRAL call -23.40% · α vs SPY -27.79% · entry $2.82 → $2.16
Entry = T+0 close
May 12, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.54%
$2.82
settled 6mo ago
T+5d
0.00%
call 0.00% · α -0.08%
$2.82
settled 5mo ago
T+20d
-23.40%
call -23.40% · α -21.68%
$2.16
settled 5mo ago
T+60d
-23.40%
call -23.40% · α -27.79%
$2.16
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

HUTCHMED reported that all resolutions at its May 12, 2026 Annual General Meeting were passed, including re-election of directors, reappointment of auditors, and approval of share issuance/repurchase mandates and a new share option scheme. This is a routine procedural filing with no material financial or operational impact.

Key Facts

  • All six ordinary resolutions and one special resolution passed with overwhelming shareholder support (over 89% for each).
  • Resolutions included re-election of 9 directors, reappointment of PricewaterhouseCoopers as auditors, general mandate to issue shares, mandate to repurchase shares, and adoption of 2026 Share Option Scheme.
  • Total issued shares as of AGM date: 872,335,120; no treasury shares held.
  • Share issuance mandate (Resolution 4) passed with 99.9851% in favor; share repurchase mandate (Resolution 5) passed with 99.9933% in favor.

Financial Impact

No financial impact from this filing; mandates authorize potential future share issuance or repurchase but no amounts disclosed.

Risk Factors

  • Potential dilution if share issuance mandate is exercised, though no current plans disclosed.
  • No material business updates provided; reliance on other pipeline or earnings news for stock movement.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001648257-26-000031
Document: hcm-20260512x6k.htm0001648257-26-000031
Document: 0001648257-26-000031-index-headers.html0001648257-26-000031
Document: 0001648257-26-000031-index.html0001648257-26-000031
Document: 0001648257-26-000031.txt0001648257-26-000031
5 reports for HMDCF
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for HMDCF — sortable, filterable
TypeNow
May 21, 2026
22w ago
6-K
BULLISH ★ 7/10
$2.16 $2.16· 0.00%▼ −4.30%$2.16 (+0.00%)
May 12, 2026
24w ago
6-K
NEUTRAL ★ 1/10
$2.82 $2.16▼ −23.40%▼ −27.79%$2.16 (−23.40%)
Apr 29, 2026
25w ago
6-K
BULLISH ★ 7/10
$2.82 $2.16▼ −23.40%▼ −27.52%$2.16 (−23.40%)
Apr 9, 2026
28w ago
6-K
NEUTRAL ★ 5/10
$2.82 $2.90▲ +2.84%▼ −7.94%$2.16 (−23.40%)
Apr 9, 2026
28w ago
6-K
NEUTRAL ★ 2/10
$2.82 $2.90▲ +2.84%▼ −7.94%$2.16 (−23.40%)
Showing 5 of 5

US Market Status

Market Open — Closes in 6h 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026